SAN DIEGO, Nov. 9, 2021 /PRNewswire/ -- Viking
Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage
biopharmaceutical company focused on the development of novel
therapies for metabolic and endocrine disorders,
today announced that its chief executive officer, Brian Lian, Ph.D., will deliver a corporate
presentation as part of the Stifel 2021 Virtual Healthcare
Conference. The conference, which will take place November 15-17, 2021, is being conducted with a
virtual format.
Details for this presentation are as follows:
- Stifel 2021 Virtual Healthcare Conference
Conference
Date: November 15-17, 2021
Presentation Time/Date: 4:00 – 4:30
p.m. Eastern on Tuesday, November 16,
2021
Format: Virtual conference
A webcast of the Stifel presentation may be accessed via a link
on the Viking Therapeutics website in the Investors & Media
section under Webcasts. Additionally, a replay of the webcast
will be available on the Viking website following the
conferences.
About Viking Therapeutics, Inc.
Viking Therapeutics is a clinical-stage biopharmaceutical
company focused on the development of novel, orally available,
first-in-class or best-in-class therapies for the treatment of
metabolic and endocrine disorders. Viking's research and
development activities leverage its expertise in metabolism to
develop innovative therapeutics designed to improve patients'
lives. The company's clinical programs include VK2809, a
novel, orally available, small molecule selective thyroid hormone
receptor beta agonist for the treatment of lipid and metabolic
disorders, which is currently being evaluated in a
Phase 2b study for the treatment of biopsy-confirmed
non-alcoholic steatohepatitis (NASH) and fibrosis. In a Phase
2a trial for the treatment of non-alcoholic fatty liver disease
(NAFLD) and elevated LDL-C, patients who received VK2809
demonstrated statistically significant reductions in LDL-C and
liver fat content compared with patients who received
placebo. The company's second clinical candidate is VK0214, a
novel, orally available, small molecule selective thyroid hormone
receptor beta agonist for the potential treatment of X-linked
adrenoleukodystrophy (X-ALD). VK0214 is currently being
evaluated in a Phase 1b clinical
trial in patients with the adrenomyeloneuropathy (AMN) form of
X-ALD. The company holds exclusive worldwide rights to a
portfolio of five therapeutic programs, including those noted
above, which are based on small molecules licensed from Ligand
Pharmaceuticals Incorporated. The company is also developing a
wholly-owned series of novel dual agonists of the GLP-1 and GIP
receptors, for the potential treatment of metabolic disorders.
For more information about Viking Therapeutics, please
visit www.vikingtherapeutics.com. Follow Viking on Twitter
@Viking_VKTX.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/viking-therapeutics-to-present-at-stifel-2021-virtual-healthcare-conference-301420159.html
SOURCE Viking Therapeutics, Inc.